QNTM — QUANTUM BIOPHARMA LTD
As of Q2 2026, 5 SEC-registered investment managers reported holding QNTM (QUANTUM BIOPHARMA LTD) in their latest 13F filings, with a combined reported value of $181.43K across 50.12K shares. That is +116.0% by share count (+26.92K shares) versus the previous quarter, while reported value moved +61.9%. Ownership is concentrated: the five largest holders account for 100.0% of reported value and the top ten for 100.0%.
Compared with the prior quarter, 2 opened new positions, 2 added to existing stakes. 13F holdings are quarter-end snapshots, so these moves reflect positioning as of Q2 2026, not real-time trading.
QNTM is classified in the Health Care sector.
All figures on this page are computed from SEC Form 13F quarterly filings. 13F filers disclose long positions of $100,000 or more within 45 days of quarter end; short positions, options overlays and intra-quarter trades are not included, so treat the numbers as a quarterly snapshot of institutional ownership rather than real-time positioning.
Q2 2026 — 5 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| UBS Group AG history | 33.41K | $120.93K | 0.00% | Add |
| Citadel Advisors history | 15.86K | $57.42K | 0.00% | Hold |
| Morgan Stanley history | 600 | $2.17K | 0.00% | New |
| Wells Fargo & Co history | 250 | $907 | 0.00% | Add |
| Citigroup Inc history | 1 | $4 | 0.00% | New |
Q1 2026 — 3 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| Citadel Advisors history | 15.86K | $76.62K | 0.00% | Hold |
| UBS Group AG history | 7.24K | $34.95K | 0.00% | Add |
| Wells Fargo & Co history | 100 | $477 | 0.00% | New |
Q4 2025 — 5 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| Citadel Advisors history | 15.86K | $115.80K | 0.00% | New |
| UBS Group AG history | 1.71K | $12.48K | 0.00% | Reduce |
| JPMorgan Chase & Co history | 577 | $4.21K | 0.00% | Reduce |
| Morgan Stanley history | 243 | $1.77K | 0.00% | Reduce |
| Bank of America Corp history | 4 | $29 | 0.00% | Reduce |
Q3 2025 — 4 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| UBS Group AG history | 8.75K | $143.57K | 0.00% | Reduce |
| Morgan Stanley history | 2.56K | $42.05K | 0.00% | Add |
| JPMorgan Chase & Co history | 736 | $12.07K | 0.00% | Reduce |
| Bank of America Corp history | 100 | $1.64K | 0.00% | New |
Q2 2025 — 3 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| UBS Group AG history | 45.88K | $929.13K | 0.00% | Add |
| JPMorgan Chase & Co history | 897 | $18.16K | 0.00% | New |
| Morgan Stanley history | 131 | $2.65K | 0.00% | Reduce |
Q1 2025 — 2 funds
| Fund | Shares | Value | Portfolio Weight | Change |
|---|---|---|---|---|
| Morgan Stanley history | 2.53K | $19.52K | 0.00% | New |
| UBS Group AG history | 1.61K | $12.44K | 0.00% | New |
New Positions (Q2 2026)
- Morgan Stanley 600 sh · $2.17K
- Citigroup Inc 1 sh · $4
Fully Exited (vs previous quarter)
No tracked fund fully exited this quarter.
Fund Position History — shares by quarter (top 8 funds)
| Fund | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 |
|---|---|---|---|---|---|---|---|
| UBS Group AG | 33.41K | 7.24K | 1.71K | 8.75K | 45.88K | 1.61K | — |
| Citadel Advisors | 15.86K | 15.86K | 15.86K | — | — | — | — |
| Morgan Stanley | 600 | — | 243 | 2.56K | 131 | 2.53K | — |
| Wells Fargo & Co | 250 | 100 | — | — | — | — | — |
| Citigroup Inc | 1 | — | — | — | — | — | — |
| JPMorgan Chase & Co | — | — | 577 | 736 | 897 | — | — |
| Bank of America Corp | — | — | 4 | 100 | — | — | 1 |
| Fidelity Management & Research (FMR) | — | — | — | — | — | — | 1 |
▲ Bought Low (fund opened/added, stock rose ≥5% next quarter) ▼ Sold High (fund reduced, stock fell ≥5% next quarter)
Drag / scroll to zoom · Default shows the most recent year · Annotations come from quarterly fund actions in 13F filings · Hover a marker for details